BPC-157 Near Me: No Counter Sells 10 mg for $24.50

Six kinds of business turn up for this search, and none of them is a dispensary for an approved product, because there is no approved product.

The pattern is consistent. Proximity is what is being sold, and where BPC-157 is genuinely present it came from the same unapproved research-supply market a buyer could reach directly. The one thing a local address adds is a person to hold accountable, and only if they can name the batch and the laboratory that assayed it.

This is where most pages on the subject are simply out of date, so the sequence is worth setting out plainly.

BPC-157 has never been approved for any indication in the United States and has no USP or NF monograph. In September 2023 FDA placed it in Category 2 for nominated bulk substances, those that may present significant safety risks, and nearly every article you will find stops at that sentence. In April 2026 FDA removed BPC-157 from Category 2 after the nominations were withdrawn, for further evaluation. Removal is not promotion to Category 1 and it is not approval. At the Pharmacy Compounding Advisory Committee meeting of 23 and 24 July 2026, the committee narrowly recommended BPC-157 for the 503A Bulks List. That recommendation is non-binding, BPC-157 does not appear in 21 CFR 216.23, and FDA has issued no final determination.

Net position: unapproved, no longer in Category 2, recommended but not listed. Under section 503A a pharmacy may compound from a bulk substance that has a USP or NF monograph, is a component of an approved drug, or appears on that list. BPC-157 meets none of the three, so the local counter cannot exist on a settled basis regardless of how confidently it is advertised. Our regulatory page takes the timeline apart in full.

BPC-157 is unusual here. With most research peptides a local clinic is selling something else under a loose label, but wellness clinics and med spas genuinely do list BPC-157 injections by name, at a price, on a menu beside NAD+ infusions and vitamin drips. The advertising is not the misdirection. What it cannot describe is a lawful dispensing route, because there is not one.

Work through what has to be true. There is no approved BPC-157 product, so nothing is being dispensed against a marketing authorisation. There is no USP or NF monograph and no entry in 21 CFR 216.23, so nothing is being compounded under section 503A on settled ground. What is left is unapproved material sourced from the same research-supply market anyone can reach, administered in a room with a consultation attached. The room does not change what is in the vial.

It is worth knowing what the claims rest on, too. No human efficacy trial of BPC-157 has reported. The first controlled test, NCT07437547, a Phase 2 in acute hamstring muscle strain with 120 participants, began on 2 February 2026 and is not due to reach primary completion before 14 February 2027. Anything a clinic tells you about outcomes today is extrapolated from rat and cell work, much of it from a single research group in Zagreb.

Three questions settle the rest in a phone call. What is the batch code on the vial you would use. Which laboratory issued the certificate for that batch, and can I see it. Where was the material purchased. A clinic that answers all three is at least being legible about what it holds. One that answers with a treatment plan and a price has answered a different question. Our MOTS-c local-supply page covers the same pattern for a compound where the clinics really are selling something else.

Strip the geography out of the query and what remains is a supply question with a mundane answer: research suppliers ship it, domestically, in a few days.

A US-held stock position is worth more than a nearby storefront for reasons that have nothing to do with distance. There is no import VAT, no customs clearance and no chance of a border detention. Dispatch is same day before 2pm CST, transit is measured in days rather than weeks, and a return address in the same country is a real form of recourse if something is wrong. The domestic supply page compares that against an overseas route line by line.

What to do when the box arrives is short. Check the vial is intact and the powder is a dry cake or film with nothing loose in the liquid sense. Read the batch code on the label, then confirm it is the batch on the certificate rather than a certificate for some other batch. Ascension publishes two third-party assays per batch, from Kovera Labs (batch #12-05260628) and MZ Biolabs (batch #12-01260229). Then store it cold and dry until it is used, which the storage guide covers.

Part of what people are looking for when they search locally is a price to sanity-check. There is not one, and the reason is the same as everything else on this page: coverage and cash pricing both run through an approved product with a national drug code and a formulary position, and BPC-157 has neither. Nothing is dispensed against a prescription, so no claim exists for a pharmacy to submit, and the FDA approved drug database returns no entry to price against.

So the only comparables are other research listings, and the honest way to compare them is per milligram landed rather than per vial. The 10 mg vial at $24.50 with the code is $2.45 per milligram, $1.225 per 500 mcg and $0.245 per 100 mcg. Quantity tiers take 3%, 5% and 10% off the $49.00 list price, giving $47.53, $46.55 and $44.10 a vial, all of which are well above the code rate. Free carriage starts at $250, which eleven discounted vials reach at $269.50.

One figure needs its qualifier wherever it appears. The Wolverine Stack shows $2.25 per milligram, which is lower, but the stack is 10 mg of BPC-157 blended with 10 mg of TB-500 in one vial, so that rate averages two compounds. On the BPC-157 alone it works out at $4.50 per milligram. A clinic quoting a per-milligram figure without saying what is in the vial is quoting the same kind of number. The full breakdown sits on our price page.

A dispensed medicine arrives with its arithmetic finished. A research vial arrives with none of it done, which is the practical difference between the local result you wanted and the parcel you get.

The vial holds 10 mg of lyophilised BPC-157, which is 10,000 mcg, and no concentration at all until water is added. With 2 mL of bacteriostatic water it becomes 5 mg/mL, which is 200 units on a U-100 barrel, so 10 units draws 500 mcg and every unit holds 50 mcg. With 1 mL it becomes 10 mg/mL and 100 units, and 10 units draws 1 mg. The vial cost $24.50 either way and the cost per 100 mcg stays at $0.245; the only thing that changed is the smallest quantity the barrel can resolve.

Nobody sets that for you and no pharmacist checks it. Our reconstitution guide and syringe measurement guide cover the handling, and the calculator will run any volume you enter. These are laboratory handling figures for research material, not instructions for anything else.

One last point for anyone in a tested sport, since local clinics rarely raise it: WADA prohibits BPC-157 at all times under class S0, non-approved substances, and there is no exemption available for a substance with no approved therapeutic use.